Indoco Remedies Limited
Valuation (93/100) does the heavy lifting; quality (10/100) is the drag.
Buy zoneSolvency riskOur blended model reads Indoco Remedies Limited as a Sell at 40/100. We put fair value near ₹439.64; at ₹241.39 that leaves roughly 82% upside, so the stock screens undervalued by 82%. On 17.4x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 21% below its 52-week high of ₹304.44 and 47% above the low of ₹163.86. Financial health scores 23/100, in the grey band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹276.25 implies about 14% upside across 4 analysts. It clears 5 of 12 investability checks, with durability 10, valuation 85 and momentum 66 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹351.72.
Analyst views
1-year price
EOD · 2026-09-1552-week range
-20.71% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell40Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: -10.1%
- Fail: Low debt (D/E < 0.5): 1.17x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 22%
- No data: Earnings growing
- Fail: Net margin ≥ 10%: -5.2%
- Fail: Current ratio > 1.5: 1.13
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 1.93
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter60.9%
- Institutions19.7%
- Public & other19.4%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Opportunities
- Revenue growing (22% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~82% below our estimated fair value.
Bear case
Weaknesses
- Low return on equity (-10.1%).
About Indoco Remedies Limited
Indoco Remedies Limited manufactures and markets pharmaceutical formulations and active ingredients for domestic and international markets. Its product portfolio spans gastrointestinal, anti-infective, respiratory, dental, vitamin and mineral, urological, ophthalmological and dental, dermatological, pain relief, cardiac, anti-diabetic, and gynecological therapies, including branded generic analgesics and topical treatments.
Indoco Remedies Limited — frequently asked questions
Is Indoco Remedies Limited a buy, hold or sell?
StocksWizard currently rates Indoco Remedies Limited (INDOCO) a Sell, based on a blended score of 40/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Indoco Remedies Limited's fair value?
Our blended DCF and relative-valuation model estimates Indoco Remedies Limited's fair value at about ₹439.64, versus a current price of ₹241.39 — roughly 82% upside. On that basis the stock looks undervalued by 82%.
Is Indoco Remedies Limited financially healthy?
Indoco Remedies Limited scores 23/100 on our financial-health model, placing it in the grey band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Indoco Remedies Limited's share price performed?
Indoco Remedies Limited is up 4% over three months, and last traded at ₹241.39. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.